In recent years, research and development of new therapies designed to increase vascular remodeling (such as intravitreal injections of vascular endothelial growth factor (anti-VEGF therapy)) radically changed the treatment of the “wet” AMD type, thus allowing physicians to make significant progress in this field [11]. Here, VEGFA is linked to age-related macular degeneration.